BACKGROUND AND AIM: Endothelial dysfunction in hypertensive type-2 diabetic patients is associated with increased levels of circulating soluble adhesion molecules (SAM). SAM participate in the development of diabetic macroangiopathy and microangiopathy. The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on SAM levels in hypertensive type-2 diabetic patients. METHODS:Forty type-2 diabetic patients with never-treated hypertension were randomly assigned to two groups. One group (FDTV) received 2/180 mg once a day; the other group received T 2 mg once a day. Study drugs were administered for three months in both groups. VCAM-1, ICAM, and E-selectin were measured by ELISA at the beginning and end of the study. Patients were evaluated monthly for blood pressure, fasting serum glucose, and adverse events. Statistical analysis was performed with ANOVA. RESULTS: Both therapeutics regimens reduced significantly the levels of the SAM tested. When both groups were compared, we did not find a significant difference in ICAM and E-selectin reduction. However, VCAM-1 presented a significantly greater reduction (p = 0.022) in the trandolapril-verapamil group. No patient suffered adverse events. CONCLUSION: Our results show that FDTV produces a greater reduction of VCAM-1 circulating levels than trandolapril alone. This may explain some of the beneficial effects of this fixed dosed combination that are non-related to its antihypertensive effects.
RCT Entities:
BACKGROUND AND AIM: Endothelial dysfunction in hypertensive type-2diabeticpatients is associated with increased levels of circulating soluble adhesion molecules (SAM). SAM participate in the development of diabetic macroangiopathy and microangiopathy. The aim of this study was to compare the effect of trandolapril (T) and its fixed-dose combination with verapamil (FDTV) on SAM levels in hypertensive type-2diabeticpatients. METHODS: Forty type-2 diabeticpatients with never-treated hypertension were randomly assigned to two groups. One group (FDTV) received 2/180 mg once a day; the other group received T 2 mg once a day. Study drugs were administered for three months in both groups. VCAM-1, ICAM, and E-selectin were measured by ELISA at the beginning and end of the study. Patients were evaluated monthly for blood pressure, fasting serum glucose, and adverse events. Statistical analysis was performed with ANOVA. RESULTS: Both therapeutics regimens reduced significantly the levels of the SAM tested. When both groups were compared, we did not find a significant difference in ICAM and E-selectin reduction. However, VCAM-1 presented a significantly greater reduction (p = 0.022) in the trandolapril-verapamil group. No patient suffered adverse events. CONCLUSION: Our results show that FDTV produces a greater reduction of VCAM-1 circulating levels than trandolapril alone. This may explain some of the beneficial effects of this fixed dosed combination that are non-related to its antihypertensive effects.
Authors: Alberto F Rubio-Guerra; Ana K Garro-Almendaro; Cesar I Elizalde-Barrera; Juan A Suarez-Cuenca; Montserrat B Duran-Salgado Journal: Ther Adv Cardiovasc Dis Date: 2016-12-08
Authors: Alberto F Rubio-Guerra; Hilda Vargas-Robles; Jose J Lozano Nuevo; Cesar I Elizalde-Barrera; Saul Huerta-Ramirez; Bruno A Escalante-Acosta Journal: Exp Clin Cardiol Date: 2012
Authors: Alberto Francisco Rubio-Guerra; Hilda Vargas-Robles; Luz Maria Ramos-Brizuela; Bruno Alfonso Escalante-Acosta Journal: Integr Blood Press Control Date: 2010-09-29
Authors: Alberto F Rubio-Guerra; David Castro-Serna; Cesar I Elizalde Barrera; Luz M Ramos-Brizuela Journal: Integr Blood Press Control Date: 2009-11-23